Literature DB >> 24099633

Differential effects of eugenol against hepatic inflammation and overall damage induced by ischemia/re-perfusion injury.

Dalia M Abd El Motteleb1, Sally A Selim, Ahmed M Mohamed.   

Abstract

Liver injuries, liver tumor resection, and liver transplantation are known to be responsible for ischemia/reperfusion (I/R) injury that, in turn, gives rise to liver damage. This study was undertaken to investigate the possible protective effect of eugenol against the damage induced by I/R in rat livers as well as to explore possible mechanisms of action. Male rats were divided into four groups: sham-operated, I/R only, and two groups that received 10 or 100 mg eugenol/kg/day (Eug10 and Eug100, respectively) for 15 days by gavage and were then subjected to I/R, i.e. an ischemia induced for 45 min followed by re-perfusion for 6 h. The rats were euthanized and liver tissues and blood collected for examination. The results showed that I/R induced massive hepatic structural and functional damage. Eug10-treated rats had improvement in both liver function and structure, and inhibition of I/R-induced increases in serum myeloperoxidase (MPO), tumor necrosis factor (TNF)-α, as well as hepatic nuclear factor-κB (NF-κB) p65 and caspase-3 expression. Eug10 treatment also inhibited the degree of loss in reduced glutathione (GSH) and of rise in malondialdehyde (MDA) levels in liver tissues induced by I/R. In contrast, augmentation of liver damage induced by I/R was noted in Eug100-treated rats, with these hosts displaying significant increases in oxidant, inflammatory, and apoptotic markers relative to levels seen in I/R-only rats. The results of the present study provide the first evidence that a low dose of eugenol may protect the liver against I/R injury in part by decreasing levels of lipid peroxidation, down-regulating inflammatory mediators, and inhibiting apoptosis, and that a larger dose amplifies the liver injury via oxidant and inflammatory effects.

Entities:  

Keywords:  Caspase-3; MDA; NF-κB; eugenol; hepatic I/R

Mesh:

Substances:

Year:  2013        PMID: 24099633     DOI: 10.3109/1547691X.2013.832444

Source DB:  PubMed          Journal:  J Immunotoxicol        ISSN: 1547-691X            Impact factor:   3.000


  6 in total

1.  Eugenol-rich Fraction of Syzygium aromaticum (Clove) Reverses Biochemical and Histopathological Changes in Liver Cirrhosis and Inhibits Hepatic Cell Proliferation.

Authors:  Shakir Ali; Ram Prasad; Amena Mahmood; Indusmita Routray; Tijjani Salihu Shinkafi; Kazim Sahin; Omer Kucuk
Journal:  J Cancer Prev       Date:  2014-12

Review 2.  An Overview on the Anti-inflammatory Potential and Antioxidant Profile of Eugenol.

Authors:  Joice Nascimento Barboza; Carlos da Silva Maia Bezerra Filho; Renan Oliveira Silva; Jand Venes R Medeiros; Damião Pergentino de Sousa
Journal:  Oxid Med Cell Longev       Date:  2018-10-22       Impact factor: 6.543

3.  Eugenol protects the transplanted heart against ischemia/reperfusion injury in rats by inhibiting the inflammatory response and apoptosis.

Authors:  Wei Feng; Longyu Jin; Qianyi Xie; Lihua Huang; Zhibin Jiang; Ying Ji; Chunyun Li; Linfei Yang; Dianjun Wang
Journal:  Exp Ther Med       Date:  2018-08-13       Impact factor: 2.447

4.  Oleic Acid Protects against Hepatic Ischemia and Reperfusion Injury in Mice by Inhibiting AKT/mTOR Pathways.

Authors:  Jianrong Guo; Tao Zhang; Jian Gu; Kailin Cai; Xiuling Deng; Ke Chen; Kun Huang; Guobin Wang; Huili Li; Jiliang Wang
Journal:  Oxid Med Cell Longev       Date:  2019-12-13       Impact factor: 6.543

5.  Eugenol Administration Improves Liver Damage Induced by a Fructose-Rich Diet.

Authors:  Abbass Ali Niazi; Fatemeh Kourkinejad Gharaei; Zahra Saebinasab; Maryam Maleki; Fatemeh Maghool; Fatemeh Fereidooni; Tahereh Safari
Journal:  Adv Biomed Res       Date:  2021-11-26

6.  Eugenol Attenuates Cerebral Ischemia-Reperfusion Injury by Enhancing Autophagy via AMPK-mTOR-P70S6K Pathway.

Authors:  Xiaowei Sun; Dongyan Wang; Tingting Zhang; Xuejian Lu; Fangfang Duan; Lili Ju; Xiaotong Zhuang; Xicheng Jiang
Journal:  Front Pharmacol       Date:  2020-02-21       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.